Andrew Bayly

Dr Andy Bayly is a Principal Medicinal Chemist at CHARM therapeutics.  Prior to this, he worked at Healx Therapeutics and Vertex Pharmaceuticals where he worked extensively on rare diseases and application of chemogenomic libraries to probe biology of phenotypic high throughput screens.  Andy received his doctorate from Imperial College under the supervision of Prof. Alan Spivey and subsequently contributed to a Wellcome Trust funded project with the late Prof. Chris Abell.